Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced its schedule for the publication of financial information for 2017.
Event | Date* | |
2016 Q4 Cash Position | January 27, 2017 | |
2017 Q1 Cash Position | April 26, 2017 | |
2016 Full-Year Financial Update and Statements | April 27, 2017 | |
Annual General Meeting | May 31, 2017 | |
2017 First-Half Financial Update and Statements | July 28, 2017 | |
2017 Q3 Cash Position | October 26, 2017 | |
2017 Q4 Cash Position | January 25, 2018 |
*Subject to modification.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170126005674/en/